Yorhe Fluid Intelligent Control Co Ltd

002795.CS

Yonghe Intelligent Control Completes Industrial and Commercial Registration for Transfer of 51% Equity and Creditor's Rights in Taixing Pule

Yonghe Fluid Intelligent Control Co., Ltd. announced that the transfer of 51% equity and creditor's rights in its holding subsidiary Pule New Energy Technology (Taixing) Co., Ltd. has completed industrial and commercial registration, with the transferee being Hainan Zhironghui Technology Co., Ltd. The transaction went through six rounds of listing, with no intended transferee found in the first five rounds. In the sixth round, the listing base price was adjusted to 1.00 yuan, and the deal was ultimately concluded at 101 yuan. On February 4, 2026, the two parties signed the Property Rights Transaction Contract, covering the 51% equity in Taixing Pule and the company's creditor's rights against Taixing Pule, with principal and interest totaling 168.77551 million yuan. On February 12, 2026, the handover procedures for control rights and creditor's rights transfer were completed.

002795.CS

Jiemian·17dRead more →

002795.CS▲

Yonghe Intelligent Control swings to net profit of 63.39 million yuan in first half of 2026

Yonghe Intelligent Control disclosed its 2026 semi-annual report. In the first half, total operating revenue was 302 million yuan, down 17.68 percent year on year, while net profit attributable to the parent company was 63.39 million yuan, swinging from a loss a year earlier. Deducted non-recurring net loss was 16.64 million yuan, compared with a loss of 35.20 million yuan in the same period last year. Net cash flow from operating activities was negative 69.45 million yuan, versus negative 829,900 yuan a year earlier. During the reporting period, basic earnings per share were 0.14 yuan, and the weighted average return on equity was 15.46 percent, up 22.99 percentage points year on year. Total non-recurring gains and losses were 80.03 million yuan, including 80.70 million yuan in gains on disposal of non-current assets.

002795.CS ▲

中国证券报·26dRead more →

002795.CS▼

Yonghe Intelligent Control expects first-half 2026 profit of 50.5 million to 70.5 million yuan, swinging to profit year-on-year

Yonghe Intelligent Control disclosed its earnings forecast, expecting to achieve a net profit attributable to the parent company of 50.5 million yuan to 70.5 million yuan in the first half of 2026, compared with a loss of 37.6197 million yuan in the same period last year, swinging from loss to profit year-on-year. The company expects operating revenue for the same period to be between 271 million yuan and 331 million yuan, a year-on-year decline, mainly due to reduced sales orders caused by Sino-US trade friction. The growth in net profit attributable to the parent company mainly stems from the recognition of a relatively large amount of investment income from the sale of a subsidiary during the period. Deducted non-recurring profit or loss is expected to be a loss of 11 million yuan to 19.6 million yuan, compared with a loss of 35.1966 million yuan in the same period last year. Basic earnings per share are expected to be between 0.11 yuan and 0.16 yuan.

002795.CS ▼

中国证券报·67dRead more →

002795.CS▼

Yonghe Intelligent Control sells its last hospital starting at 1 yuan, as cross-sector healthcare push rapidly recedes

Yonghe Intelligent Control is transferring its 70 percent stake in Liangshan High-Tech Oncology Hospital at a listing price of 1 yuan, drawing a line under its cross-sector healthcare strategy. The hospital was an asset the company acquired in December 2021 for 31.5 million yuan, and just one month ago the listing price was still 1.87 million yuan. Previously, the company's hospital stakes in Dazhou and Xi'an were both sold at a floor price of 1 yuan, with final transaction prices of just 101 yuan and 201 yuan respectively, while the Kunming hospital was sold for 16.683 million yuan, equivalent to a 15 percent discount on its 108 million yuan acquisition price. Yonghe Intelligent Control has posted losses for four consecutive years from 2022 to 2025, with cumulative losses of about 619 million yuan, and its hospitals have racked up combined losses of nearly 80 million yuan. The cross-sector hospital investment fever among listed companies is rapidly cooling. Shinva Medical has offloaded 11 hospitals in five years, DADONG FANG transferred its 80 percent stake in Jinhua Lianji Hospital for 1 yuan, and companies such as China Resources Sanjiu and Yibai Pharmaceutical have also been divesting hospital assets.

002795.CS ▼600587.CG ▼

读创财经·72dRead more →